Business
Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in Toulouse, France
Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Proposed transaction would seamlessly align with Sandoz strategic objective of capitalizing on projected USD 300 billion biosimilar market opportunity over next 10 years[1]Intended acquisition would reinforce in-house biosimilar development and manufacturing capabilities, while creating additional strategic flexibilitySandoz would acquire Just-Evotec Biologics (JEB) activities in Toulouse, France, including pr
About this update from Sandoz Group Ltd
[{"type":"image","alt":"Sandoz Group","displaySize":"","headline":null,"caption":"Sandoz Group","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":41,"url":"https://media.zenfs.com/en/globenewswire.com/f12e92daa0852ddf107832c313b07d25"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/qaCYsKqoASJVSMd1vUCp9Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTU3O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/f12e92daa0852ddf107832c313b07d25","width":300,"height":41}},"lazy":false},{"type":"text","content":"Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules","length":72,"tagName":"p"},{"type":"text","content":"MEDIA RELEASE","length":13,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Proposed transaction would seamlessly align with Sandoz strategic objective of capitalizing on projected USD 300 billion biosimilar market opportunity over next 10 years[1]","length":172,"tagName":"p"}]},{"val":[{"type":"text","content":"Intended acquisition would reinforce in-house biosimilar development and manufacturing capabilities, while creating additional strategic flexibility","length":148,"tagName":"p"}]},{"val":[{"type":"text","content":"Sandoz would acquire Just-Evotec Biologics (JEB) activities in Toulouse, France, including proprietary platform for integrated development and advanced continuous manufacturing","length":176,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":496,"olType":false},{"type":"text","content":"Basel, July 30, 2025 Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, announced today that it has signed a non-binding term sheet with Evotec SE. This paves the way for Sandoz to potentially acquire 100% of the issued and outstanding equity interests of Just–Evotec Biologics EU SAS for an amount of around USD 300 million, which owns the J.POD biologics development and manufacturing facility in Toulouse, France.","length":462,"tagName":"p"},{"type":"text","content":"Richard Saynor, CEO of Sandoz, said: “We aim to capitalize on the projected USD 300 billion biosimilar market opportunity over the next decade. The intended acquisition is fully in line with our strategy to reinforce in-house biosimilar capabilities, while creating additional strategic flexibility. Following successful completion, the Toulouse site would be ...